Effect of heparin on human corneal fibroblast proliferation in vitro with and without growth factor stimulation.
BACKGROUND
The outcome of keratorefractive procedures such as PRK and LASIK is limited by the wound-healing process in the corneal stroma, which gives rise to complications such as haze formation and regression. The proliferation and matrix synthesis of corneal stromal fibroblasts is the central element of the wound-healing process. In order to develop new therapeutic strategies to reduce wound-healing intensity, we investigated the effect of heparin on the proliferation of cultured human corneal stromal fibroblasts (HCF) alone and in the presence of growth factors.


METHODS
Primary cultures of HCF were established using epithelium and endothelium-free explants. Secondary cultures of HCF (first passage), cultured in WM/F12 supplemented with 10 microg/ml transferrin and 10 microg/ml thyroglobulin (LR-1 medium), 1% fetal calf serum (FCS) and 10% FCS were used to determine the effect of heparin on the proliferation of HCF in concentrations ranging from 12.5 microg/ml to 5000 microg/ml. Cell number was determined using the CASY 1 cell counter system. Modulation of HCF proliferation by heparin (50 microg/ml and 2000 microg/ml) was also investigated under serum-free conditions and in the presence of bFGF, EGF and PDGF-BB.


RESULTS
Addition of heparin led to a dose-dependent inhibition of proliferation after 6 days of incubation, which was statistically significant for 500-5000 microg heparin/ ml (FCS 1%) and for 200-5000 microg heparin/ml (FCS 10%). IC50 values for this effect were determined to be approximately 700 microg heparin/ml. When cultured under serum-free conditions (LR-1), a significant reduction of cell number was only observed with 5000 microg heparin/ml. There was no significant modulation of PDGF-BB-, bFGF-, or EGF-stimulated cell proliferation by heparin at concentrations of 50 microg/ml and 2000 microg/ml after 6 days of incubation.


CONCLUSIONS
Our observations indicate that heparin can inhibit proliferation of HCF effectively. The results of the present study could eventually pave the way to prevent anterior stromal haze formation and regression after keratorefractive surgery.
Denk
P O
PO
University Eye Hospital Tübingen, Germany. Oliver.Denk@uni-tuebingen.de
Knorr
M
M
D000925:Anticoagulants / Q000494:pharmacology*; D000077214:Becaplermin; D018929:Cell Culture Techniques; D002455:Cell Division / Q000187:drug effects; D003315:Cornea / Q000166:cytology* / Q000187:drug effects; D004815:Epidermal Growth Factor / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D005347:Fibroblasts / Q000166:cytology* / Q000187:drug effects; D005500:Follow-Up Studies; D006133:Growth Substances / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D014945:Wound Healing / Q000187:drug effects
D000925:Anticoagulants; D006133:Growth Substances; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2; D000077214:Becaplermin; D004815:Epidermal Growth Factor; D006493:Heparin